AU2003255644B2 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof - Google Patents

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof Download PDF

Info

Publication number
AU2003255644B2
AU2003255644B2 AU2003255644A AU2003255644A AU2003255644B2 AU 2003255644 B2 AU2003255644 B2 AU 2003255644B2 AU 2003255644 A AU2003255644 A AU 2003255644A AU 2003255644 A AU2003255644 A AU 2003255644A AU 2003255644 B2 AU2003255644 B2 AU 2003255644B2
Authority
AU
Australia
Prior art keywords
compound
formula
methyl
trifluoromethyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003255644A
Other languages
English (en)
Other versions
AU2003255644A1 (en
Inventor
Francoise Bono
Michael Bosch
Victor Dos Santos
Jean Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of AU2003255644A1 publication Critical patent/AU2003255644A1/en
Application granted granted Critical
Publication of AU2003255644B2 publication Critical patent/AU2003255644B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2003255644A 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof Ceased AU2003255644B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR02/07001 2002-06-07
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
AU2003255644A1 AU2003255644A1 (en) 2003-12-22
AU2003255644B2 true AU2003255644B2 (en) 2009-02-05

Family

ID=29724874

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003255644A Ceased AU2003255644B2 (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2003255645A Abandoned AU2003255645A1 (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003255645A Abandoned AU2003255645A1 (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Country Status (29)

Country Link
US (2) US7468368B2 (enExample)
EP (2) EP1513836B1 (enExample)
JP (2) JP4437075B2 (enExample)
KR (1) KR100970812B1 (enExample)
CN (1) CN100448875C (enExample)
AR (2) AR040246A1 (enExample)
AT (2) ATE336491T1 (enExample)
AU (2) AU2003255644B2 (enExample)
BR (1) BR0311828A (enExample)
CA (1) CA2487840C (enExample)
CY (2) CY1107330T1 (enExample)
DE (2) DE60305037T2 (enExample)
DK (2) DK1513835T3 (enExample)
EA (1) EA007501B1 (enExample)
ES (2) ES2264001T3 (enExample)
HR (1) HRP20041157B1 (enExample)
IS (1) IS2302B (enExample)
MA (1) MA27233A1 (enExample)
ME (1) MEP11508A (enExample)
MX (1) MXPA04012341A (enExample)
NO (1) NO329669B1 (enExample)
NZ (1) NZ537044A (enExample)
PL (1) PL208711B1 (enExample)
PT (2) PT1513835E (enExample)
RS (2) RS20050014A (enExample)
TW (2) TWI319400B (enExample)
UA (1) UA77526C2 (enExample)
WO (2) WO2003104225A1 (enExample)
ZA (1) ZA200409823B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
WO2005068445A2 (en) * 2004-01-08 2005-07-28 Syngenta Participations Ag Pesticidal heterocyclic dihaloallyl compounds
CA2572821A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2594318B1 (en) * 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
AU2008227100B2 (en) * 2007-03-15 2014-01-09 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
WO2008144764A1 (en) * 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
SG181570A1 (en) 2009-12-14 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
KR20250171415A (ko) 2018-09-18 2025-12-08 쥐에프비(에이비씨), 엘엘씨 피리다지논 및 이의 사용 방법
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173180B (es) * 1987-10-26 1994-02-07 Pfizer Procedimiento para preparar agentes ansioliticos
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
AU2003255644A1 (en) 2003-12-22
EP1513835A1 (fr) 2005-03-16
EP1513836A1 (fr) 2005-03-16
AR040246A1 (es) 2005-03-23
JP2005534661A (ja) 2005-11-17
RS52588B (sr) 2013-04-30
NO329669B1 (no) 2010-11-29
ZA200409823B (en) 2006-07-26
DK1513835T3 (da) 2006-12-27
DE60307632D1 (de) 2006-09-28
EA200401470A1 (ru) 2005-06-30
ATE325122T1 (de) 2006-06-15
CY1105784T1 (el) 2011-02-02
PT1513835E (pt) 2006-12-29
NZ537044A (en) 2006-08-31
CY1107330T1 (el) 2012-11-21
EP1513835B1 (fr) 2006-08-16
JP4437075B2 (ja) 2010-03-24
ES2264001T3 (es) 2006-12-16
MXPA04012341A (es) 2005-09-30
TW200407321A (en) 2004-05-16
KR100970812B1 (ko) 2010-07-16
CA2487840C (en) 2011-05-17
US20060167007A1 (en) 2006-07-27
UA77526C2 (en) 2006-12-15
NO20045331L (no) 2005-03-07
WO2003104225A1 (fr) 2003-12-18
DK1513836T3 (da) 2006-09-11
US7294628B2 (en) 2007-11-13
MA27233A1 (fr) 2005-02-01
TWI319400B (en) 2010-01-11
CN1675203A (zh) 2005-09-28
DE60305037T2 (de) 2006-12-14
JP2005533051A (ja) 2005-11-04
CA2487840A1 (en) 2003-12-18
US7468368B2 (en) 2008-12-23
JP4441401B2 (ja) 2010-03-31
US20050176722A1 (en) 2005-08-11
TW200400185A (en) 2004-01-01
AR040247A1 (es) 2005-03-23
HRP20041157B1 (en) 2012-11-30
HK1076110A1 (zh) 2006-01-06
BR0311828A (pt) 2005-03-29
WO2003104226A1 (fr) 2003-12-18
HRP20041157A2 (en) 2005-06-30
ES2271637T3 (es) 2007-04-16
IS2302B (is) 2007-10-15
CN100448875C (zh) 2009-01-07
KR20050008802A (ko) 2005-01-21
DE60305037D1 (de) 2006-06-08
RS20050014A (sr) 2007-06-04
IS7579A (is) 2004-12-02
EP1513836B1 (fr) 2006-05-03
PT1513836E (pt) 2006-09-29
AU2003255645A1 (en) 2003-12-22
EA007501B1 (ru) 2006-10-27
PL208711B1 (pl) 2011-05-31
MEP11508A (en) 2010-06-10
ATE336491T1 (de) 2006-09-15
PL374729A1 (en) 2005-10-31
DE60307632T2 (de) 2007-08-09
TWI283671B (en) 2007-07-11

Similar Documents

Publication Publication Date Title
AU2003255644B2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
US20100240670A1 (en) 4-[(arylmethyl)aminomethyl]piperidine derivatives, their preparation and their therapeutic application
JP4669479B2 (ja) （４−フェニルピペラジン−１−イル）アシルピペリジン誘導体、これらの調製、および治療におけるこれらの適用
IL165420A (en) Piperazinylacylpiperidine and homopiperazinylacylpiperidine derivatives, their preparation and their use in the preparation of medicaments
HK1076110B (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired